Article info

Download PDFPDF

Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to ‘2019 update of the EULAR recommendations for the management of SLE: don’t forget chloroquine’ by Figueroa-Parra et al
Free

Authors

  • Antonis Fanouriakis Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece PubMed articlesGoogle scholar articles
  • George K Bertsias Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Greece PubMed articlesGoogle scholar articles
  • Dimitrios T Boumpas Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece Joint Academic Rheumatology Program, Medical School, National and Kapodestrian University of Athens, Athens, Greece PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, 12462, Greece; afanour{at}med.uoa.gr
View Full Text

Citation

Fanouriakis A, Bertsias GK, Boumpas DT
Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to ‘2019 update of the EULAR recommendations for the management of SLE: don’t forget chloroquine’ by Figueroa-Parra et al

Publication history

  • Received May 23, 2019
  • Accepted May 24, 2019
  • First published June 8, 2019.
Online issue publication 
August 14, 2020

Article Versions